title: Effects of endokinin A/B and endokinin C/D on the antinociception properties of hemopressin in mice.
abstract: The current study evaluated the effects of hemopressin (HP) on pain modulation by endokinin A/B (EKA/B) and endokinin C/D (EKC/D) at the supraspinal level in mice. Intracerebroventricular administration of HP (10 nmol) fully antagonized the hyperalgesia induced by EKA/B (10, 30, and 100 pmol), and induced a dose-dependent potent analgesic effect. HP at different concentrations (10 pmol, 100 pmol, and 1 nmol) showed varying effects on the analgesic effect of EKA/B (3 nmol). HP extended the duration of the analgesic effect of EKC/D (3 nmol). Moreover, HP at different concentrations (10 pmol, 5 pmol, 1 pmol, and 100 fmol) co-administered with EKC/D (30 pmol) induced significant analgesia at two different time points: 5 min and 50 min. To investigate the antinociceptive mechanism, we used SR140333B and SR142801. HP (1 pmol) potentiated the analgesic effect of SR140333B (100 pmol)+EKA/B (30 pmol) in 5-10 min, while HP (100 pmol) had no effect in the analgesia induced by SR140333B (3 nmol)+EKA/B (3 nmol). HP (1 nmol) fully inhibited the analgesic effect of SR140333B (3 nmol)+EKC/D (3 nmol) or SR142801 (3 nmol)+EKC/D (3 nmol). HP (1 pmol) weakened the analgesic effect of SR142801 (100 pmol)+EKA/B (30 pmol), but HP (100pmol) strengthened the analgesic effect of SR142801 (3 nmol)+EKA/B (3 nmol). These findings may pave the way for a new strategy on investigating the interaction between tachykinins and opioids on pain modulation.
authors.affiliation: The Core Laboratory of the First Affiliated Hospital, Key Laboratory for Gastrointestinal Diseases of Gansu Province, Lanzhou University, Lanzhou 730000, China.
authors.forename: Lanxia
authors.initials: L
authors.lastname: Zhou
authors.forename: Qiaoying
authors.initials: Q
authors.lastname: Jin
authors.forename: Yinliang
authors.initials: Y
authors.lastname: Yang
authors.forename: Zhengkun
authors.initials: Z
authors.lastname: Liu
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Li
authors.forename: Shouliang
authors.initials: S
authors.lastname: Dong
authors.forename: Li
authors.initials: L
authors.lastname: Zhao
mesh_terms: D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D006454:Hemoglobins / Q000008:administration & dosage / Q000494:pharmacology*; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors; D015320:Tachykinins / Q000494:pharmacology*; D014326:Tropanes / Q000494:pharmacology
chemical_list: D000700:Analgesics; D006454:Hemoglobins; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments; D010880:Piperidines; D018042:Receptors, Neurokinin-3; D015320:Tachykinins; D014326:Tropanes; C526005:SR140333B; C473218:hemopressin; C091554:SR 142801; C486037:TAC4 protein, human